FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115978280> ?p ?o ?g. }

• W2115978280 endingPage "140" @default.
• W2115978280 startingPage "129" @default.
• W2115978280 abstract "SUMMARY Objective: To assess the effectiveness and tolerability of the management of chronic pain unrelated to cancer with controlled and sustained-release tramadol administered in a single daily dose. Material and methods: Prospective, observational, multicentric pharmacoepidemiological study. A total of 100 Pain Units in our country were involved. Patients with chronic pain unrelated to cancer that had initiated treatment with sustained and controlledrelease tramadol were included. In order to assess the effectiveness of the drug, anthropometric characteristics, type of pain, severity and effect on sleep and quality of life were recorded. Two follow-up visits were performed at one week and at one month after the beginning of the treatment and variations in the following pain scores were recorded: visual analogical scale and Lattinen test, quality of life, side effects and changes in the treatment. Results: Nine hundred and seven patients, 66.03% women and 33.97% men were included in the study. Of these, 52.92% had lumbalgia and 33,96% osteoarthritis. A significant decrease in all the pain scores was observed since the first week of treatment. The incidence of side effects was 16.8%, with a mean length of 6.3 ± 4 days. Nausea and vomiting were the side effects with the highest incidence (18.3%), followed by constipation and somnolence (10.5 and 10.3%, respectively). The highest impact of the analgesic response to controlled and sustained-release tramadol was seen in the physical condition score of the quality of life. Treatment compliance was adequate in 93.22% of the patients, while 66.38% reported satisfaction or high satisfaction with the treatment at the end of the study. Conclusions: Controlled and sustained-release tramadol was highly effective for the relief of pain since the first week of treatment. Tolerability was good, with a low rate of mild side effects. Nausea and vomiting were the side effects with the highest incidence. © 2004 Sociedad Espanola del Dolor. Published by Aran Ediciones, S.L." @default.
• W2115978280 created "2016-06-24" @default.
• W2115978280 creator A5040730766 @default.
• W2115978280 creator A5049547783 @default.
• W2115978280 date "2004-04-01" @default.
• W2115978280 modified "2023-09-23" @default.
• W2115978280 title "Efectividad, tolerabilidad y calidad de vida en el tratamiento del dolor crónico no oncológico, con tramadol de liberación controlada en dosis única diaria" @default.
• W2115978280 cites W1830252304 @default.
• W2115978280 cites W2000047289 @default.
• W2115978280 cites W2002758220 @default.
• W2115978280 cites W2041320351 @default.
• W2115978280 cites W2046488366 @default.
• W2115978280 cites W2062680754 @default.
• W2115978280 cites W2066964251 @default.
• W2115978280 cites W2148191688 @default.
• W2115978280 cites W2376963905 @default.
• W2115978280 cites W2409576557 @default.
• W2115978280 cites W42618186 @default.
• W2115978280 cites W65300678 @default.
• W2115978280 cites W2524600589 @default.
• W2115978280 hasPublicationYear "2004" @default.
• W2115978280 type Work @default.
• W2115978280 sameAs 2115978280 @default.
• W2115978280 citedByCount "3" @default.
• W2115978280 crossrefType "journal-article" @default.
• W2115978280 hasAuthorship W2115978280A5040730766 @default.
• W2115978280 hasAuthorship W2115978280A5049547783 @default.
• W2115978280 hasConcept C120665830 @default.
• W2115978280 hasConcept C121332964 @default.
• W2115978280 hasConcept C126322002 @default.
• W2115978280 hasConcept C14184104 @default.
• W2115978280 hasConcept C159110408 @default.
• W2115978280 hasConcept C197934379 @default.
• W2115978280 hasConcept C2778375690 @default.
• W2115978280 hasConcept C2779034229 @default.
• W2115978280 hasConcept C2779777798 @default.
• W2115978280 hasConcept C2779951463 @default.
• W2115978280 hasConcept C2780580376 @default.
• W2115978280 hasConcept C2780820201 @default.
• W2115978280 hasConcept C2780852908 @default.
• W2115978280 hasConcept C2781112942 @default.
• W2115978280 hasConcept C42219234 @default.
• W2115978280 hasConcept C61511704 @default.
• W2115978280 hasConcept C71924100 @default.
• W2115978280 hasConceptScore W2115978280C120665830 @default.
• W2115978280 hasConceptScore W2115978280C121332964 @default.
• W2115978280 hasConceptScore W2115978280C126322002 @default.
• W2115978280 hasConceptScore W2115978280C14184104 @default.
• W2115978280 hasConceptScore W2115978280C159110408 @default.
• W2115978280 hasConceptScore W2115978280C197934379 @default.
• W2115978280 hasConceptScore W2115978280C2778375690 @default.
• W2115978280 hasConceptScore W2115978280C2779034229 @default.
• W2115978280 hasConceptScore W2115978280C2779777798 @default.
• W2115978280 hasConceptScore W2115978280C2779951463 @default.
• W2115978280 hasConceptScore W2115978280C2780580376 @default.
• W2115978280 hasConceptScore W2115978280C2780820201 @default.
• W2115978280 hasConceptScore W2115978280C2780852908 @default.
• W2115978280 hasConceptScore W2115978280C2781112942 @default.
• W2115978280 hasConceptScore W2115978280C42219234 @default.
• W2115978280 hasConceptScore W2115978280C61511704 @default.
• W2115978280 hasConceptScore W2115978280C71924100 @default.
• W2115978280 hasIssue "3" @default.
• W2115978280 hasOpenAccess W2115978280 @default.
• W2115978280 hasVolume "11" @default.
• W2115978280 isParatext "false" @default.
• W2115978280 isRetracted "false" @default.
• W2115978280 magId "2115978280" @default.
• W2115978280 workType "article" @default.